10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
NVN Liquidation does not have enough data to calculate 10-Year ROIIC %.
NVN Liquidation 10-Year ROIIC % Historical Data
The historical data trend for NVN Liquidation's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NVN Liquidation's 10-Year ROIIC %
For the Biotechnology subindustry, NVN Liquidation's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NVN Liquidation's 10-Year ROIIC % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NVN Liquidation's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NVN Liquidation's 10-Year ROIIC % falls into.
NVN Liquidation 10-Year ROIIC % Calculation
NVN Liquidation's 10-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -35.39 (Dec. 2022) - (Dec. 2012) )
/
( 52.682 (Dec. 2022) - (Dec. 2012) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NVN Liquidation 10-Year ROIIC % Related Terms
Thank you for viewing the detailed overview of NVN Liquidation's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
NVN Liquidation (NVN Liquidation) Business Description
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOVNQ has been successfully added to your 